Chest
Translating Basic Research Into Clinical PracticeDiagnosing Tuberculosis Infection in the 21st Century: New Tools To Tackle an Old Enemy
Section snippets
Diagnosing Latent Tuberculosis Infection in the 20th Century
The biology of latent tuberculosis infection (LTBI) is poorly understood, and the condition has hitherto been defined by a positive tuberculin skin test (TST) result in an asymptomatic person exposed to tuberculosis with no clinical or radiographic signs of active tuberculosis. The clinical relevance of this definition is that it carries a small but significant forward risk of progression to active tuberculosis, which is significantly increased in persons with suppressed or immature (ie, young
Translation From Bench to Bedside
Advances in mycobacterial genomics in the late 1990s identified an M tuberculosis genomic segment that is deleted from all strains of BCG vaccine and most environmental mycobacteria, denoted region of difference-1.3 Two proteins encoded by this stretch of DNA, early secretory antigenic target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10), are strong targets of T-helper type 1 T cells in patients with M tuberculosis infection.45 Therefore, a T-cell response to these antigens could, in
Rapidly Expanding Clinical Evidence Base in the Last 5 Years
A large and rapidly growing number of clinical studies with these assays have been published since 2001. The ELISpot evidence base is comprised predominantly of studies using the Lalvani ELISpot test, which has recently been developed into the T-SPOT.TB test (Oxford Immunotec; Oxford, UK) [Table 1]. Therefore, all published studies using either of these assay formats are reviewed here, and the assays are denoted as ELISpot. For QuantiFERON-TB Gold (Cellestis; Carnegie, Australia), studies using
Clinical Performance in People at High Risk of Progression to Tuberculosis
The strategy for diagnosis and treatment of LTBI is based on targeted tuberculin testing, which targets persons at highest risk of progression from LTBI to active tuberculosis.28 This includes all recently infected people (ie, tuberculosis contacts) and people with suppressed or immature (ie, young children) cellular immune systems. Table 2, Table 3, Table 4, Table 5 summarize the performance of the tests in immunocompetent contacts, but what of the high-risk groups in whom the TST has poor
Reliability of the Blood Tests in Routine Use
Indeterminate results can arise for a variety of reasons, but the most significant cause is a failed positive control, which usually reflects underlying cellular immune suppression. Indeterminate results are quite common with ELISA in routine practice, ranging from 12 to 21%,12152529 and are associated with young age (< 5 years), old age (> 80 years),25 and immunosuppression due to a variety of causes, including HIV infection, in which indeterminate results become more common with lower CD4
Direct Comparison of the Blood Tests
Studies directly comparing the two blood tests in the same study populations have recently been published. In patients with active tuberculosis, three reports121331 compared blood tests in a total of 134 patients; the sensitivity of ELISpot was 83 to 95% compared to 74 to 83% for ELISA, and this difference was statistically significant in the largest study.13 Two studies compared the tests head-to-head in persons at risk of LTBI; in a low-prevalence country, close contacts of pulmonary
Summary of Clinical Data
The conclusions from the published studies to date are that neither blood test is confounded by BCG vaccination and both are therefore more specific than the TST. Both tests are more sensitive than the TST in active tuberculosis, with ELISpot having higher sensitivity than ELISA. ELISpot also performs well in HIV-coinfected tuberculosis patients and young children with tuberculosis, but published data with ELISA in these patient populations are lacking. In LTBI, ELISpot probably has higher
From Clinical Trials to Clinical Practice
What should clinicians do with blood test results in practice? Current national guidelines3233 recommend the use of blood tests for diagnosis of LTBI and as an adjunct for the evaluation of patients with suspected tuberculosis. But national guidelines vary, reflecting residual uncertainty about the clinical status of persons with discordant TST and blood test results. Current European guidelines, of which those published by the UK National Institute of Health and Clinical Excellence32 (NICE)
Effect of Treatment on Blood Test Results
The impact of treatment on blood test results has been studied for ELISpot in tuberculosis patients and, more recently, in persons with LTBI. In general, the magnitude of ELISpot responses declines significantly with treatment in both active tuberculosis1023 and LTBI,4041 raising the interesting possibility that the quantitative, dynamic readout of ELISpot might be used to monitor treatment response. This would be particularly useful in LTBI, for which there are no clinical or laboratory
Impact on Clinical Practice Today
The high specificity of both blood tests will lessen the number of persons inappropriately treated on the basis of false-positive TST results caused by prior BCG vaccination. This represents an enabling step for tuberculosis elimination programs in low prevalence countries where, as the prevalence of LTBI declines, an increasing proportion of positive TST results are falsely positive. High diagnostic sensitivity in young children (as evidenced for ELISpot) and immunosuppressed populations (as
References (43)
- et al.
Enhanced contact tracing and spatial tracking ofMycobacterium tuberculosisinfection by enumeration of antigen-specific T cells
Lancet
(2001) - et al.
Use in routine clinical practice of two commercial blood tests for diagnosis of infection withMycobacterium tuberculosis: a prospective study
Lancet
(2006) - et al.
Comparison of two commercial interferon-γ assays for diagnosingMycobacterium tuberculosisinfection
Eur Respir J
(2006) - et al.
Comparison of T-cell-based assay with tuberculin skin test for diagnosis ofMycobacterium tuberculosisinfection in a school tuberculosis outbreak
Lancet
(2003) - et al.
Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study
Lancet
(2004) - et al.
Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study
Clin Microbiol Infect
(2006) - et al.
Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice
J Infect
(2007) Diagnosing latent tuberculosis infection: the 100-year upgrade
Am J Respir Crit Care Med
(2001)An update on the diagnosis of tuberculosis infection
Am J Respir Crit Care Med
(2006)- et al.
Molecular analysis of genetic differences betweenMycobacterium bovisBCG and virulentM. bovis
J Bacteriol
(1996)
Rapid detection ofMycobacterium tuberculosisinfection by enumeration of antigen-specific T cells
Am J Respir Crit Care Med
Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration ofMycobacterium tuberculosis-specific T cells
Aids
Rapid effector function in CD8+ memory T cells
J Exp Med
Spotting latent infection: the path to better tuberculosis control
Thorax
Specific detection of tuberculosis infection: an interferon-γ-based assay using new antigens
Am J Respir Crit Care Med
Directex vivoanalysis of antigen-specific IFN-γ-secreting CD4 T cells inMycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment
J Immunol
Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice
Eur J Clin Microbiol Infect Dis
Discrepancy between the tuberculin skin test and the whole-blood interferon γ assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country
JAMA
Prospective evaluation of a whole-blood test usingMycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis
Clin Diagn Lab Immunol
T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure
Am J Respir Crit Care Med
Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection
Am J Respir Crit Care Med
Cited by (324)
Peritoneal tuberculosis mimicking advanced ovarian cancer case report: Laparoscopy as diagnostic modality
2021, International Journal of Surgery Case ReportsInterleukin-6 and Mycobacterium tuberculosis dormancy antigens improve diagnosis of tuberculosis
2021, Journal of InfectionCitation Excerpt :Immune diagnostic tests based on sensitized T-cells contribute largely to detection of M. tuberculosis infection. Originally – and for almost a century – the tuberculin skin test (TST) was the only available test for diagnosis of M. tuberculosis infection but limited TST specificity led to the invention of alternative methods, the so called IFNγ-release assays (IGRA; e.g. QuantiFERON, T-SPOT.TB))1. IGRA tests are based on short-term in vitro stimulation of peripheral blood immune cells and detect M. tuberculosis infection with higher specificity as compared to the TST2,3.
Advances in the diagnosis of tuberculosis- Journey from smear microscopy to whole genome sequencing
2020, Indian Journal of Tuberculosis
Professor Lalvani is a named inventor for several patents underpinning T-cell–based diagnosis filed by the University of Oxford since 1996. Regulatory approval and commercialization of the Lalvani ELISpot (T-SPOT.TB) has been undertaken by a spin-out company of the University of Oxford (Oxford Immunotec Ltd.; Oxford, UK), in which Professor Lalvani has a share of equity and to which he acts as scientific advisor in a nonexecutive capacity. The University of Oxford has a share of equity in Oxford Immunotec Ltd.
Professor Lalvani is supported by a Wellcome Senior Research Fellowship in Clinical Science.